Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients

enthalten in: The British journal of cancer | 2017

von Faivre, C. | El Cheikh, R. | Barbolosi, D. | +1

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

enthalten in: The British journal of cancer | 2011

von LeCaer, H. | Barlesi, F. | Corre, R. | +7

Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung

enthalten in: The British journal of cancer | 2005

von Barlési, F. | Pinot, D. | Legoffic, A. | +4

CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy

enthalten in: The British journal of cancer | 2005

von Barlési, F. | Tchouhadjian, C. | Doddoli, C. | +3

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients

enthalten in: The British journal of cancer | 2004

von Pujol, J. | Molinier, O. | Ebert, W. | +6